Juan Ignacio D. M.
- Country
- Spain
- Department
- Oncology
Research Overview
- Phase III Trial of BNT327 plus Combination Chemotherapy versus Placebo plus Chemotherapy in Patients with Previously Untreated Metastatic or Locally Recurrent Triple-Negative Breast Cancer
- A Phase III Multicenter Randomized Open-Label Study of Atezolizumab and Bevacizumab as Adjuvant Therapy in High-Risk Hepatocellular Carcinoma Post-Resection or Ablation
- Phase 3 Randomized Open-Label Study of OP-1250 Versus Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer Post-Endocrine and CDK4/6 Inhibitor Therapy
Data & Insights
Has run more than one trial at 44 of 238 partner sites.
Specializations
Liver Cancer Research
Specializes in investigating innovative treatments for high-risk hepatocellular carcinoma, focusing on post-surgical and post-ablation therapeutic approaches.
- Adjuvant therapy development
- Immunotherapy combinations
- Recurrence prevention strategies
Explores combined applications of anti-PD-L1 antibody treatments with targeted vascular therapies in liver cancer management.
Bladder Cancer Treatment
Dedicated to advancing treatment protocols for non-muscle invasive bladder cancer, with particular attention to immunotherapeutic interventions.
- Early-stage bladder cancer therapy
- Intravesical treatment optimization
- Combination therapy approaches
Investigates enhanced therapeutic outcomes through immunotherapy combinations with conventional bladder cancer treatments.
Breast Cancer Studies
Concentrates on longitudinal research in early-stage invasive breast cancer, with emphasis on treatment outcomes and disease progression patterns.
- Neoadjuvant therapy assessment
- Adjuvant treatment protocols
- Disease relapse patterns
Conducts comprehensive evaluation of long-term therapeutic outcomes in breast cancer treatment modalities.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.